To sum up, LPA possesses mitogenic and proinflammatory effects in RAFLS cells, and berberine can inhibit the proliferation and inflammatory phenotype of RAFLS cells through both inhibiting ATX‐mediated LPA activation and blocking LPA/LPA1/ERK/p38 MAPK signalling, which suggests a potential therapeutic target for developing anti‐RA drugs. The gene discussed is LPAR1; the disease is rheumatoid arthritis.